3rd ESTRO Forum 2015 S231 fractions) Adaptive Radiotherapy (ART) approach delivering a concomitant boost to the MRI-based residual tumour during the last 6 fractions. Materials and Methods: T3/T4N0 or N+ rectal adenocarcinoma patients (pts) were enrolled in an observational trial. Concomitant chemotherapy consisted of Oxaliplatin 100mg/m 2 on days -14, 0, +14, and 5-FU 200mg/m 2 /day from day -14 to the end of radiotherapy (day 0 is the start of radiotherapy). Radiotherapy consisted in the delivery of 41.4Gy in 18 fractions (fr) (2.3 Gy/fr) with Tomotherapy to the tumor and regional lymph-nodes (PTV) defined on CT/MRI imaging. After 9 fr, CT and MRI were repeated for the planning of the adaptive phase: PTV adapt was generated by adding a 5mm margin to the residual tumour visible on MRI images. In the last 6 fr, a boost of 3.0 Gy/fr (total dose: 45.6 Gy in 18 fr) was delivered to PTV adapt while concomitantly delivering 2.3 Gy/fr to PTV outside PTV adapt . Data regarding acute toxicity and outcome were analyzed. Results: From September 2009 to April 2014, 50 pts completed the preoperative treatment and were evaluable. No G4 toxicity occurred: the G3 toxicity was gastrointestinal only: diarrhoea in 9/50 pts (18%), and proctitis in 2/50 (4%). Diarrhoea started before the adaptive phase in all cases and all affected patients were women. Two pts achieved complete response (cCR) and refused surgery, 1 pt was lost, 1 pt had early distant progression. Forty-six pts underwent surgery (43 R0, 3 R1): thirteen pts (28 %) had pathological complete response (pCR); 22/46 (47%) showed TRG3 response: 13/46 (28%) and 6/46 (13%) had ≤5%, and 6-10% residual viable cells, respectively. Regarding the two patients with cCR who refused surgery, one is still cCR after 54 months while the other had local relapse and underwent transanal resection 1 year after treatment. Concerning treatment feasibility, two pts interrupted radiotherapy after 7 and 13 fr respectively, the remaining pts (48/50=96%) completed the treatment, and the median duration of RT was 25 days (22-36 days). 43/50 pts (86%) and 40/50 pts (80%) received the full dose of oxaliplatin and FU, respectively: 14% of pts received moderately reduced doses (60%-90%), and only two pts (4%) received less than 60% of the planned dose. Conclusions: This study confirms that adaptive boost strategy is feasible with an acceptable G3 toxicity rate and a very encouraging tumour response rate. The results suggest that there should still be room for further dose escalation with the aim of increasing pCR and/or cCR rates.
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The practical use of our 1,5 Tesla MRI/HDR treatment room for patients with cervical cancer K.M. Van Vliet -van den Ende 1 , A.A.C. De Leeuw 1 , R.I. Schokker 1 , W.A. Bazen 1 , A.A. Louis 1 , I.M. Jurgenliemk-Schulz 1 1 UMC Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands Purpose/Objective: In 2011, we build a dedicated Brachytherapy (BT) treatment suite, equipped with an HDR afterloader and a 1.5 T MR scanner. In this study, we evaluated in which way the MR scanner influences the position verification of applicator and organs at risk (OAR) and induces adaptive interventions during the process of brachytherapy for cervical cancer patients.
Materials and Methods:
We collected the data from 16 patients (32 applications), treated with the MR compatible Utrecht tandem/ovoid intracavitary/interstitial applicator (Elekta Brachytherapy, The Netherlands) during the last year. The brachytherapy treatment schedule consisted of two applications and delivery of two HDR fractions each (7 Gy/fr). Applicator insertion, repeated MR imaging and HDR dose delivery were performed in our treatment room equipped with a 1.5 T MRI scanner and a conventional afterloader (Elekta Brachytherapy, The Netherlands). Multiple MR scans during the process of BT were taken (see table) . For this analysis we evaluated how often we actually performed direct adaptive interventions aiming at the reduction of uncertainties in dose delivery. Before the first applicator placement, MR images were taken to evaluate tumor extension and the need for needles. If needles were used, short sequence MR scans could be taken directly after the insertion to verify applicator and needle placement and allow adaptation before taking the definitive scans for treatment planning. Prior to dose delivery, MR scanning was repeated for position verification of the applicator parts in relation to the tumor and in order to detect anatomical changes of the OAR's. Adaptive interventions included repositioning of interstitial needles, insertion of rectal tubes to deflate gas or to change the position of the rectum, and variations in bladder filling mainly to reduce bowel dose.
Results:
In 18 of 25 applications with interstitial needles short sequence MR scans were taken to check needle position resulting in repositioning in 3 cases. In 10 of the 16 patients we did interventions with respect to the OAR's, 4 times for bladder and 7 times for rectum. Moreover, we better learned to individualize the use of rectal probes and bladder fillings: One year ago we left the rectal probe in place during irradiation but we discovered it not only deflated gas but also could displace the rectum position. In some cases it brought the rectum closer into the high dose areas. This resulted in a change of procedure. Nowadays we usually insert the probe for deflation and then remove it before scanning and irradiation. Conclusions: Having a combined 1,5 T MRI/HDR treatment room makes it possible to perform position verifications and adaptive interventions that helps to reduce uncertainties in brachytherapy and to deliver the prescribed dose as accurate as possible according to plan.
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Robustness study on pitch and roll rotations for multiple cranial metastases using VMAT P. Mancosu 1 , A. Gaudino 1 , F. Lobefalo 1 , G. Maggi 2 , P. Navarria 2 , V. Palumbo 1 , G. Reggiori 1 , A. Stravato 1 , M. Scorsetti 2 , S. Tomatis 1 1 Humanitas Cancer Center, Medical Physics Unit of Radiotherapy, Milano, Italy 2 Humanitas Cancer Center, Radiotherapy and Radiosurgery, Milano, Italy Purpose/Objective: Volumetric modulated arc therapy (VMAT) was demonstrated to be feasible for radiosurgical treatment of multiple cranial metastases (MCM). The pitch and roll inclusions of 107 brain patients treated in our institute on the PerfectPitch™ 6 degrees of freedom couch revealed 65.5% and 31.8% had pitch and/or roll compensations greater than 1° and 2°. We have investigated the dosimetric consequences of inaccurate pitch and roll
